Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted EBITDA Margin of 11601.78% for Q1 2026, up 89.5% sequentially from 110481.25% in Q3 2025.

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported EBITDA Margin for 3 years, with the latest figure at 11601.78% in Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 11601.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28426.61% (changed N/A YoY) and the FY2025 annual result came in at 90740.62%, down 9065438.0% from the prior year.
EBITDA Margin grew to 11601.78% in Q1 2026 per CNTB's latest filing, from 110481.25% in the prior quarter.
Over five years, EBITDA Margin peaked at 1135.85% in Q3 2024 and troughed at 110481.25% in Q3 2025.
A 3-year average of 30512.72% and a median of 11601.78% in 2026 frame the typical range for EBITDA Margin.
The widest YoY moves for EBITDA Margin: up 10934540 bps in 2025, down 10934540 bps in 2025.
Over 3 years, EBITDA Margin stood at 1378.08% in 2024, then tumbled by 7917 bps to 110481.25% in 2025, then surged by 89 bps to 11601.78% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 11601.78%, 110481.25%, and 27966.67% for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	-635.98%

Download Data